

Press Releases

All Years ▾
<input type="text" value="Search"/>
<input type="button" value="Go"/>

[Advanced Search](#)

DEC 9, 2009

[**Perrigo Confirms Filing for Generic Version of Clobex® Spray and Announcement of Lawsuit by Galderma and Dermalogix**](#)

DEC 7, 2009

[**Perrigo Company Launches Labeling Initiative to Identify Gluten-free Products**](#)

Gluten-free labeling program an industry first for over-the-counter pharmaceuticals

NOV 19, 2009

[**Perrigo Company To Present at the Sidoti Emerging Growth Conference**](#)

NOV 9, 2009

[**/CORRECTION – Perrigo Company/**](#)

In the news release, Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference, issued 09-Nov-2009 by Perrigo Company over PR Newswire, we are advised by the company that in the first paragraph, the conference date and time should

NOV 9, 2009

[**Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference**](#)

NOV 2, 2009

[Perrigo Reports Record Earnings and Raises Full Year Adjusted EPS Guidance](#)

NOV 2, 2009

[Perrigo Company Divests Israel Cosmetics Business for 205 Million New Israeli Shekels](#)

OCT 29, 2009

[Perrigo Company Announces Dividend Increase](#)

OCT 19, 2009

[Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009](#)

OCT 19, 2009

[Perrigo Announces Dismissal of Duac® Patent Litigation](#)

OCT 13, 2009

[Perrigo Confirms Filing for Generic Version of Men's Rogaine® Foam](#)

OCT 6, 2009

[Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350](#)

SEP 21, 2009

[Perrigo Company To Host Investor Day](#)

SEP 21 2009

JUN 21, 2009

[Perrigo Acquires ANDA for Generic Version Duac® Gel From KV Pharmaceutical](#)

AUG 18, 2009

[Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for Fiscal 2009](#)

- Full-year revenue from continuing operations increased \$277 million, or 16 percent, to a record \$2 billion - Adjusted income from continuing operations for the full year increased 13 percent to \$175 million, or \$1.87 per share - GAAP income from continu

AUG 13, 2009

[Perrigo Company Announces Quarterly Dividend](#)

AUG 4, 2009

[Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009](#)

AUG 3, 2009

[Perrigo Announces FDA Approval for Generic Version of NASACORT® AQ](#)

JUL 13, 2009

[Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges](#)

JUN 24, 2009

[Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal® Solution and Announcement of Lawsuit by Sepracor/UCB](#)

MAY 7, 2009

[Perrigo Reports Record Third Quarter](#)

MAY 6, 2009

[Perrigo Company Announces Quarterly Dividend](#)

MAR 24, 2009

[Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% \(Lotion\)](#)

MAR 17, 2009

[Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin® and Announcement of Lawsuit by Stiefel](#)

FEB 20, 2009

[Perrigo Begins Shipments of Ibuprofen PM](#)

Show per
page

[«](#) [1](#) [...](#) [26](#) [27](#) [28](#) [29](#) [30](#) [31](#) [32](#) [...](#) [38](#) [»](#)



<https://investor.perrigo.com/press-releases?l=25&o=700>